Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23157234 | 0.91 | CA4 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL18196315 | 0.91 | CA4 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10234328 | 0.82 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL18535888 | 0.80 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17151421 | 0.80 | CA1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3976751 | 0.78 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL2636287 | 0.78 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3241488 | 0.78 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL12227837 | 0.78 | CA1 (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30676990 | 0.78 | CA1 (0.65) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954823-B1 | MEMBRANE FOR A DEWATERING PRESS | MAXI PRESS ELASTOMERTECHNIK GMBH (DE) | 2024-05-08 | — | — | EP | claimed |
| US-11786600-B2 | Cliptac composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | claimed |
| CN-114280552-A | Sidelobe cancellation method for radar strong clutter region | 武汉滨湖电子有限责任公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3954823-A1 | MEMBRANE FOR A DEWATERING PRESS | MAXI-PRESS Elastomertechnik GmbH (DE) | 2022-02-16 | — | — | EP | claimed |
| US-20260071198-A1 | CRISPR ENZYMES AND SYSTEMS WITH MODIFIED PAM SPECIFICITY | THE BROAD INSTITUTE, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12517131-B2 | Methods for labeling eukaryotic cells from a multicellular organism as well as for treating and/or diagnosing a cancer using modified monosaccharide compounds | DIAMIDEX (FR) | 2026-01-06 | — | — | US | disclosed |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | TARGIMMUNE THERAPEUTICS AG (CH) | 2026-01-01 | — | — | US | disclosed |
| WO-2025238236-A1 | POLYPLEXES OF NUCLEIC ACIDS AND TARGETED CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL | TARGIMMUNE THERAPEUTICS AG (CH) | 2025-11-20 | — | — | WO | disclosed |
| EP-4649160-A1 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS | Nantes Université (FR) | 2025-11-19 | — | — | EP | disclosed |
| EP-4649137-A1 | METHODS FOR CELL SURFACE REMODELING | Nantes Université (FR) | 2025-11-19 | — | — | EP | disclosed |
| US-20250332286-A1 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUSES | CENTRE NAT RECH SCIENT (FR) | 2025-10-30 | — | — | US | disclosed |
| EP-4017859-A1 | ALKYL QUARTERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | Caamtech, LLC (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220146516-A1 | METHODS FOR LABELING EUKARYOTIC CELLS FROM A MULTICELLULAR ORGANISM AS WELL AS FOR TREATING AND/OR DIAGNOSING A CANCER USING MODIFIED MONOSACCHARIDE COMPOUNDS | DIAMIDEX (FR) | 2022-05-12 | — | — | US | disclosed |
| EP-3990434-A1 | COMPOUNDS HAVING ANTIMALARIAL ACTIVITY | Nanyang Technological University (SG) | 2022-05-04 | — | — | EP | disclosed |
| US-20220112162-A1 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | CAAMTECH, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| CN-114280552-A | Sidelobe cancellation method for radar strong clutter region | 武汉滨湖电子有限责任公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114189815-A | Method and apparatus for terminal communication in mobile communication system | 三星电子株式会社 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022047580-A1 | HYDROXYLATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2022-03-10 | — | — | WO | disclosed |
| WO-2018057430-A1 | SYNTHESIS OF BACKBONE MODIFIED MORPHOLINO OLIGONUCLEOTIDES AND CHIMERAS USING PHOSPHORAMIDITE CHEMISTRY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071198-A1 | CRISPR ENZYMES AND SYSTEMS WITH MODIFIED PAM SPECIFICITY | CPSF1, CPSF6, CPN1 | CA1 3113/4885CA2 2663/4885CA7 2301/4885 |
| US-20260000771-A1 | PSMA-TARGETING LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | PSMA1, PSMA3, PSMA2 | CA1 150/4885CA2 507/4885CA7 767/4885 |
| US-20260000700-A1 | TARGETED LINEAR CONJUGATES COMPRISING POLYETHYLENEIMINE AND POLYETHYLENE GLYCOL AND POLYPLEXES COMPRISING THE SAME | CTDSP1, POLM, MCTS1 | CA1 2387/4885CA2 2927/4885CA7 4147/4885 |
| US-11786600-B2 | Cliptac composition | UBE3C, CBLC, STUB1 | CA1 3846/4885CA2 4609/4885CA7 4539/4885 |
| US-20250332286-A1 | CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUSES | AMDHD2, AADAC, ALDH1A2 | CA1 2289/4885CA2 1907/4885CA7 720/4885 |
| US-20220112162-A1 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | SLC18A1, HNMT, TPH1 | CA1 2883/4885CA2 1048/4885CA7 1608/4885 |
| US-20220146516-A1 | METHODS FOR LABELING EUKARYOTIC CELLS FROM A MULTICELLULAR ORGANISM AS WELL AS FOR TREATING AND/OR DIAGNOSING A CANCER USING MODIFIED MONOSACCHARIDE COMPOUNDS | ALG1, ALG8, FUCA1 | CA1 2165/4885CA2 2876/4885CA7 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.